Dinucleotide mRNA Cap Analogs with Ribose Modifications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for in vitro synthesis of capped mRNA often result in the 3′-OH of the cap moiety acting as a nucleophile, leading to the synthesis of isomeric RNAs that can be problematic for downstream processes such as translation and crystallization studies, due to the propensity of the cap to attach in reverse orientation.
Innovation Solution
Development of novel cap analogs with specific modifications at the 2′ and 3′ positions of the ribose ring, such as double- and triple-methylated cap analogs, which ensure the cap attaches in the forward orientation, improving transcription and translation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If standard cap analog (m7GpppG) is used for in vitro transcription, then transcription can proceed, but the 3'-OH of the cap moiety acts as a nucleophile leading to reverse orientation attachment and formation of isomeric RNAs
Solution Approach 1:
The patent introduces specific modifications at localized positions (2'-OH and/or 3'-OH groups) of the cap analog ribose ring to create asymmetric structures. These localized modifications prevent reverse orientation attachment without affecting the overall transcription process, thereby maintaining ease of manufacture while improving orientation specificity.
Solution Approach 2:
The invention employs asymmetric cap analog structures where the 2'-OH and/or 3'-OH groups are differentially modified (e.g., one methylated, one hydroxyl retained, or different substituent patterns). This asymmetry creates a directional preference for forward orientation attachment during transcription, eliminating the formation of isomeric RNAs while maintaining compatibility with standard transcription systems.
2Reliability
If excess m7GpppG is used to increase capping efficiency, then more transcripts are capped, but total RNA yield decreases due to GTP becoming rate-limiting for elongation
Solution Approach 1:
The patent changes the chemical parameters of the cap analog by introducing 2'- and 3'-modifications that alter its reactivity and binding properties. These parameter changes enable the cap analog to function effectively at lower concentrations, improving capping efficiency without depleting GTP pools and thereby maintaining high total RNA yields.
Solution Approach 2:
The invention creates modified versions (analogues) of the standard cap structure that replicate the essential capping function while introducing structural improvements. These copied structures with modifications at 2'-OH and 3'-OH positions achieve superior performance in both capping efficiency and overall transcription productivity.
3Productivity
If standard cap analog is used, then transcription proceeds but downstream processes such as translation and crystallization are problematic due to isomeric RNA formation
Solution Approach 1:
By introducing specific local modifications at the 2'-OH and 3'-OH positions of the cap analog, the patent ensures that only forward orientation transcripts are produced. This local structural change improves downstream process compatibility (translation and crystallization) without reducing transcription throughput, as the modifications do not interfere with the transcription mechanism itself.
Solution Approach 2:
The patent converts the potential harm of 3'-OH reactivity (which causes reverse orientation attachment) into a benefit by strategically modifying the 3'-OH group or creating an asymmetric environment where the 3'-OH cannot act as a nucleophile in reverse orientation. This transforms the problematic reactivity into a feature that ensures exclusive forward orientation attachment, improving downstream application reliability.
Data Source
AI summary
Novel cap analogs which are easily synthesized, resulting in high levels of capping efficiency and transcription and improved translation efficiencies are provided. Such caps are methylated at the N7 position of one or both guanosines of the dinucleotide cap as well as at the 3′ position on the ribose ring. Substituent groups on the ribose ring also result in the cap being incorporated in the forward orientation. Also provided are methods useful for preparing capped analogs and using mRNA species containing such analogs are also contemplated herein, as well as kits containing the novel cap analogs.